WO2012172345A3 - Traitement d'états associés à l'allergie - Google Patents

Traitement d'états associés à l'allergie Download PDF

Info

Publication number
WO2012172345A3
WO2012172345A3 PCT/GB2012/051355 GB2012051355W WO2012172345A3 WO 2012172345 A3 WO2012172345 A3 WO 2012172345A3 GB 2012051355 W GB2012051355 W GB 2012051355W WO 2012172345 A3 WO2012172345 A3 WO 2012172345A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine receptor
cxcr1
cxcr2
patient
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2012/051355
Other languages
English (en)
Other versions
WO2012172345A2 (fr
Inventor
Graham Cotton
Ola Winqvist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ITH Immune Therapy Holdings AB
Original Assignee
ITH Immune Therapy Holdings AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ITH Immune Therapy Holdings AB filed Critical ITH Immune Therapy Holdings AB
Publication of WO2012172345A2 publication Critical patent/WO2012172345A2/fr
Publication of WO2012172345A3 publication Critical patent/WO2012172345A3/fr
Priority to US14/105,628 priority Critical patent/US9726666B2/en
Anticipated expiration legal-status Critical
Priority to US15/629,713 priority patent/US10408832B2/en
Priority to US15/629,705 priority patent/US10429385B2/en
Priority to US15/629,700 priority patent/US10422800B2/en
Priority to US15/629,708 priority patent/US10401357B2/en
Priority to US15/629,691 priority patent/US10451620B2/en
Priority to US15/629,697 priority patent/US10502736B2/en
Priority to US16/537,224 priority patent/US20190361020A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3206—Organic carriers, supports or substrates
    • B01J20/3208—Polymeric carriers, supports or substrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
    • B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
    • B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3268—Macromolecular compounds
    • B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Anesthesiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode de traitement d'un état allergique consistant à appliquer du sang périphérique d'un patient ou sujet sur une colonne d'aphérèse chargée d'un support solide comprenant un réactif de liaison pouvant se lier spécifiquement à un récepteur de chimiokines, éventuellement le récepteur de chimiokines CCR3, CXCR1, CXCR2 et/ou CCR2, immobilisé directement ou indirectement sur le support, éliminant ainsi un récepteur de chimiokines, éventuellement des cellules exprimant CCR3, CXCR1, CXCR2 et/ou CCR2 à partir du sang périphérique du patient ou sujet. L'invention concerne également diverses méthodes de diagnostic compagnon, ainsi que des réactifs de liaison utiles.
PCT/GB2012/051355 2011-06-13 2012-06-13 Traitement d'états associés à l'allergie Ceased WO2012172345A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US14/105,628 US9726666B2 (en) 2011-06-13 2013-12-13 Diagnosing and treating inflammatory diseases
US15/629,697 US10502736B2 (en) 2011-06-13 2017-06-21 Treating multiple sclerosis
US15/629,713 US10408832B2 (en) 2011-06-13 2017-06-21 Treating mental disorders
US15/629,691 US10451620B2 (en) 2011-06-13 2017-06-21 Treating conditions associated with metabolic syndrome
US15/629,708 US10401357B2 (en) 2011-06-13 2017-06-21 Treating cancer
US15/629,705 US10429385B2 (en) 2011-06-13 2017-06-21 Treating conditions associated with sepsis
US15/629,700 US10422800B2 (en) 2011-06-13 2017-06-21 Treating respiratory conditions
US16/537,224 US20190361020A1 (en) 2011-06-13 2019-08-09 Treating respiratory conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496195P 2011-06-13 2011-06-13
US61/496,195 2011-06-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/051345 Continuation-In-Part WO2012172336A2 (fr) 2011-06-13 2012-06-13 Traitement de maladies inflammatoires de la peau

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2012/051350 Continuation-In-Part WO2012172340A2 (fr) 2011-06-13 2012-06-13 Traitement de troubles mentaux
US14/105,628 Continuation-In-Part US9726666B2 (en) 2011-06-13 2013-12-13 Diagnosing and treating inflammatory diseases

Publications (2)

Publication Number Publication Date
WO2012172345A2 WO2012172345A2 (fr) 2012-12-20
WO2012172345A3 true WO2012172345A3 (fr) 2013-03-07

Family

ID=46317441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/051355 Ceased WO2012172345A2 (fr) 2011-06-13 2012-06-13 Traitement d'états associés à l'allergie

Country Status (1)

Country Link
WO (1) WO2012172345A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12636417B2 (en) 2020-09-21 2026-05-26 Belgian Volition Srl Device for inline monitoring of free nucleosomes in blood

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017979A1 (en) * 1999-03-11 2003-01-23 Matthias Mack Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases
DE102005036505A1 (de) * 2004-07-30 2006-06-01 Adexter Gmbh Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung zur Behandlung von Krankheiten des Menschen
WO2007133147A1 (fr) * 2006-05-12 2007-11-22 Ibd Column Therapies International Ab Procédé et moyens pour traiter les maladies inflammatoires chroniques de l'intestin
WO2008059066A1 (fr) * 2006-11-17 2008-05-22 Haemopep Pharma Gmbh Nouveaux dérivés de chimiokine de ccl14, synthèse et utilisation en tant que médicaments pour le traitement de maladies allergiques
WO2010029317A2 (fr) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Traitement d’états inflammatoires

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537362A (ja) 1999-02-22 2002-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ビオチン化ケモカイン抗体複合体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017979A1 (en) * 1999-03-11 2003-01-23 Matthias Mack Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases
DE102005036505A1 (de) * 2004-07-30 2006-06-01 Adexter Gmbh Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung zur Behandlung von Krankheiten des Menschen
WO2007133147A1 (fr) * 2006-05-12 2007-11-22 Ibd Column Therapies International Ab Procédé et moyens pour traiter les maladies inflammatoires chroniques de l'intestin
WO2008059066A1 (fr) * 2006-11-17 2008-05-22 Haemopep Pharma Gmbh Nouveaux dérivés de chimiokine de ccl14, synthèse et utilisation en tant que médicaments pour le traitement de maladies allergiques
WO2010029317A2 (fr) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Traitement d’états inflammatoires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVID CHANTRY ET AL: "Chemokines in Allergy", CURRENT DRUG TARGETS- INFLAMMATION & ALLERGY, vol. 1, no. 1, 1 January 2002 (2002-01-01), pages 109 - 116, XP055038300 *
NIKHIL YAWALKAR ET AL: "Enhanced Expression of Eotaxin and CCR3 in Atopic Dermatitis", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 113, no. 1, 1 July 1999 (1999-07-01), pages 43 - 48, XP055038047, ISSN: 0022-202X, DOI: 10.1046/j.1523-1747.1999.00619.x *
PEASE JAMES E: "Asthma, allergy and chemokines", CURRENT DRUG TARGETS, vol. 7, no. 1, 1 January 2006 (2006-01-01), pages 3 - 12, XP008156147, ISSN: 1389-4501, Retrieved from the Internet <URL:http://www.benthamdirect.org/pages/article/1/117/asthma-allergy-and-chemokines.html> [retrieved on 20120913] *
T J WILLIAMS ET AL: "Eotaxin and CCR3 as therapeutic targets in asthma and allergy", CHEMOKINES 2, 1 January 2003 (2003-01-01), Paris, XP055038313, Retrieved from the Internet <URL:http://www.pasteur.fr/applications/euroconf/chemokines2/Williams.pdf> [retrieved on 20120917] *

Also Published As

Publication number Publication date
WO2012172345A2 (fr) 2012-12-20

Similar Documents

Publication Publication Date Title
WO2012172341A3 (fr) Traitement du cancer
Allen et al. Biological and psychological markers of stress in humans: Focus on the Trier Social Stress Test
WO2010029317A8 (fr) Traitement d&#39;états inflammatoires
NZ592473A (en) Urinary biomarkers for predicting long-term dialysis
HUP1200205A2 (en) Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
WO2010054004A3 (fr) Extraction de l&#39;acide nucléique sur des surfaces de verre courbes
WO2010118035A3 (fr) Biomarqueurs de surveillance du traitement des maladies neuropsychiatriques
EP2349381A4 (fr) Dispositif, système et méthode d&#39;assistance cardiaque
WO2011146179A3 (fr) Appareil et procédé de purification des protéines
WO2011117357A3 (fr) Pile flexible à combustible biologique, dispositif et procédé associés
BRPI0720599A2 (pt) Sistema de hidrogenação, e, métodos de hidrogenação de gordura ou óleo, de ativação de um catalisador de hidrogenação e de redução das gorduras trans produzidas durante a hidrogenação de gorduras insaturadas
WO2010025321A3 (fr) Procédé de traitement de patients souffrant de sclérose en plaques avec des anticorps anti-il2r
EA033141B1 (ru) Сшитые кристаллы белка а и их применение
WO2008012650A3 (fr) Dispositif d&#39;immunochromatographie utilisé pour le diagnostic de maladies a partir d&#39;un échantillon
WO2011163533A3 (fr) Extraction en une étape de certaines molécules d&#39;un liquide et de tissus corporels
WO2011095501A8 (fr) Procédé de réduction de complexité
WO2014093051A3 (fr) Cellules souches cardiaques et leurs procédés d&#39;identification et d&#39;utilisation
HK1258712A1 (zh) 抗衰老药物制剂
EP2547397A4 (fr) Système pour le diagnostic et le traitement de symptômes diabétiques
WO2010009129A3 (fr) Méthodes de traitement de maladies auto-immunes utilisant des anticorps cd4
WO2012172336A3 (fr) Traitement de maladies inflammatoires de la peau
EP2344106A4 (fr) Dispositif, système et méthode d&#39;assistance cardiaque
WO2012172337A3 (fr) Traitement de maladie cardiovasculaire
WO2012172344A3 (fr) Traitement d&#39;états associés à la sepsie
WO2012172346A3 (fr) Traitement de maladies respiratoires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12727920

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12727920

Country of ref document: EP

Kind code of ref document: A2